Breaking Finance News

Merus (US:MRUS) target price raised to $28.00, issued a report today by RBC Capital

Yesterday Merus (US:MRUS) traded -0.81% lower at $15.50. Merus’s 50-day moving average is $15.72 and its 200-day moving average is $21.83. The last stock price is down -29.68% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 4,054 shares of MRUS traded hands, down from an average trading volume of 6,625

Merus (US:MRUS) had its target price raised to $28.00 by RBC Capital in a report released 9/15/2017. The new target price indicates a possible upside of 0.81% based on the company's last stock close price.

Performance Chart

Merus (US:MRUS)

With a total market value of $0, Merus has with a one year low of $10.15 and a one year high of $29.75 .

A total of 4 brokerages have released a report on MRUS. zero equity analysts rating the company a strong buy, zero equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $16.28.

Brief Synopsis About Merus (US:MRUS)

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *